JHS Svendgaard Laboratories Limited has informed the Exchange regarding Appointment of Ms Ms Dahiya And Associates and Ms VK Khosla Co as Other of the company w.e.f. August 12, 2025.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JHS Svendgaard Laboratories reported its Q1 FY26 (ended June 30, 2025) results, showing revenue from operations of Rs. 2,345.41 lakhs (slightly lower than Rs. 2,448.39 lakhs in Q1 FY25) and a net profit of Rs. 105.57 lakhs, compared to a loss of Rs. 62.80 lakhs in the same quarter last year. EPS stood at Rs. 0.12. The Board appointed M/s V.K. Khosla & Co. as Statutory Auditors and M/s Dahiya & Associates as Secretarial Auditors, both for five-year terms (FY26–FY30), subject to shareholder approval. The Board also deferred the approval of the JHS Svendgaard Employee Stock Option Scheme – 2025, saying it needs a comprehensive review. Additionally, the Audit Committee was reconstituted after Mr. Mukul Pathak's directorship tenure ended, with Kapil Minocha as the new Chairperson.
The turnaround to a Rs. 105.57 lakh profit from a prior-year loss is a positive signal, though revenue dipped marginally. The change of statutory auditors and deferral of the ESOP scheme introduce some uncertainty and may be watched by shareholders. The audit committee changes are routine but worth noting for governance tracking.